Replimune's Second FDA Rejection: Layoffs Signal Binary-Risk Collapse for Biotech CFD Traders

Event Summary

On April 10, 2026, the U.S. Food and Drug Administration issued a second Complete Response Letter (CRL) rejecting Replimune Group, Inc.'s (NASDAQ: REPL) resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec), an oncolytic immunotherapy targeting advanced melanoma in combination with Bristol Myers Squibb's Opdivo. As reported by FierceBiotech and STAT News, this follows an initial rejection in July 2025 and a resubmission backed by an open letter from 22 trial researchers urging FDA re-review.

CEO Sushil Patel publicly disputed the decision, citing a changed review team and ignored feedback from prior Type A meetings. According to Morningstar/Dow Jones, the company announced immediate job cuts and U.S. manufacturing scale-back. Shares fell approximately 20% intraday, dropping from a prior close of $5.91 to $4.76 by 11:05 a.m. ET, per BioSpace reporting. The company's own February 2025 SEC filing had warned a second rejection could render RP1 "no longer viable."

Leverage Impact Analysis

This is a classic binary-event collapse — the most dangerous environment for leveraged CFD traders on CoinUnited.io, where stock CFDs can be traded with up to 2000x leverage and zero trading fees.

Consider a trader holding a 50x long REPL CFD opened at $5.91: the ~20% intraday drop to $4.76 translates to a 1,000% loss on margin at that leverage level — a total wipeout many times over, triggering automatic liquidation well before the bottom. Even at modest 10x leverage, a 20% adverse move erases the full margin on a position sized without stop-loss buffers.

Key risk factors for leveraged traders now:

• -Continued downside risk: No clear FDA re-engagement path until Phase 3 data (expected January 2029). Further selling pressure is plausible on thin volume in a depleted single-asset.
• -Gap risk: FDA CRLs are typically released pre-market or intraday, leaving no window to exit leveraged positions before the initial move materializes.
• -Funding rate / rollover cost: Monitor overnight holding costs on CoinUnited.io for REPL CFDs, as elevated volatility can increase spreads on thinly traded small-caps post-shock.

Position sizing discipline is critical: the 2026 Stocks Market Outlook consistently flags clinical-stage biotech as the highest binary-risk category in equities.

Cross-Market Impact

The direct spillover is sector-contained. The State Street SPDR S&P Biotech ETF (XBI) faces modest negative pressure, as the rejection reinforces the FDA's tightening stance on single-arm trial approvals under current biologics leadership — a headwind for multiple accelerated-approval candidates across small-cap oncology.

Broader indices — the S&P 500 Index and NASDAQ 100 Index — are unlikely to see material impact given REPL's micro-cap status. Bristol Myers Squibb carries indirect exposure through Opdivo's combo label opportunity, though its diversified portfolio limits the read-through. Forex, commodities, and crypto markets have no meaningful linkage to this event.

Trading Considerations

Key levels to monitor: the $4.76 intraday low (April 10) represents immediate support; a breach opens a path toward prior multi-year lows. Any FDA Type A meeting request or Phase 3 interim data disclosure before January 2029 would be the primary re-rating catalyst to the upside. Delisting risk escalates if the RP1 program is formally terminated and cash runway becomes a concern — watch subsequent SEC filings for burn rate disclosures.

For sector traders, XBI's reaction relative to the broader NASDAQ 100 will signal whether this is being read as Replimune-specific or as a broader FDA policy signal for accelerated-approval biotech.

Trade Avidity Biosciences, Inc. on CoinUnited.io

Trade RNAM with up to 1000xx leverage → | Create Free Account